FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1958987550> ?p ?o ?g. }

• W1958987550 endingPage "841" @default.
• W1958987550 startingPage "831" @default.
• W1958987550 abstract "The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry, or molecular genetics is complementary but not diagnostic. Risk-stratification: Prognosis of patients with MDS can be calculated using a number of scoring systems. In general, all these scoring systems include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most commonly used system still is probably the International Prognostic Scoring System (IPSS). IPSS is being replaced by the new revised score IPSS-R.Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, and more recently cytogenetic and mutational profiles. Goals of therapy are different in lower risk patients than in higher risk. In lower risk, the goal is to decrease transfusion needs and transformation to higher risk disease or AML, as well as to improve survival. In higher risk, the goal is to prolong survival. Current available therapies include growth factor support, lenalidomide, hypomethylating agents, intensive chemotherapy, and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia, and a chromosome 5 alteration. 5-Azacitidine and decitabine have activity in higher risk MDS. 5-Azacitidine has been shown to improve survival in higher risk MDS. A number of new molecular lesions have been described in MDS that may serve as new therapeutic targets or aid in the selection of currently available agents. Additional supportive care measures may include the use of prophylactic antibiotics and iron chelation. Management of progressive or refractory disease: At the present time there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options include participation in a clinical trial or cytarabine based therapy and stem cell transplantation." @default.
• W1958987550 created "2016-06-24" @default.
• W1958987550 creator A5061026876 @default.
• W1958987550 date "2015-08-21" @default.
• W1958987550 modified "2023-10-15" @default.
• W1958987550 title "Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management" @default.
• W1958987550 cites W1499045657 @default.
• W1958987550 cites W1501742295 @default.
• W1958987550 cites W1581590112 @default.
• W1958987550 cites W1648783221 @default.
• W1958987550 cites W1796660362 @default.
• W1958987550 cites W187238933 @default.
• W1958987550 cites W1928159695 @default.
• W1958987550 cites W1964809738 @default.
• W1958987550 cites W1970101456 @default.
• W1958987550 cites W1970566157 @default.
• W1958987550 cites W1974687153 @default.
• W1958987550 cites W1978522934 @default.
• W1958987550 cites W1983973479 @default.
• W1958987550 cites W1988907854 @default.
• W1958987550 cites W1990482377 @default.
• W1958987550 cites W1993236149 @default.
• W1958987550 cites W1998367819 @default.
• W1958987550 cites W1998931089 @default.
• W1958987550 cites W2000252768 @default.
• W1958987550 cites W2000837214 @default.
• W1958987550 cites W2000926243 @default.
• W1958987550 cites W2006753987 @default.
• W1958987550 cites W2014903824 @default.
• W1958987550 cites W2015776863 @default.
• W1958987550 cites W2016055354 @default.
• W1958987550 cites W2017468796 @default.
• W1958987550 cites W2019634948 @default.
• W1958987550 cites W2021333892 @default.
• W1958987550 cites W2021572674 @default.
• W1958987550 cites W2022240113 @default.
• W1958987550 cites W2026134786 @default.
• W1958987550 cites W2028751390 @default.
• W1958987550 cites W2029010638 @default.
• W1958987550 cites W2032532104 @default.
• W1958987550 cites W2033556677 @default.
• W1958987550 cites W2034585262 @default.
• W1958987550 cites W2034898311 @default.
• W1958987550 cites W2037576870 @default.
• W1958987550 cites W2038912451 @default.
• W1958987550 cites W2040855010 @default.
• W1958987550 cites W2049370950 @default.
• W1958987550 cites W2052285621 @default.
• W1958987550 cites W2066053804 @default.
• W1958987550 cites W2066210952 @default.
• W1958987550 cites W2070152906 @default.
• W1958987550 cites W2071287509 @default.
• W1958987550 cites W2072082513 @default.
• W1958987550 cites W2076367236 @default.
• W1958987550 cites W2079671946 @default.
• W1958987550 cites W2081279521 @default.
• W1958987550 cites W2081391009 @default.
• W1958987550 cites W2081895311 @default.
• W1958987550 cites W2087821794 @default.
• W1958987550 cites W2093845572 @default.
• W1958987550 cites W2099071696 @default.
• W1958987550 cites W2103020543 @default.
• W1958987550 cites W2106082819 @default.
• W1958987550 cites W2106292925 @default.
• W1958987550 cites W2106339572 @default.
• W1958987550 cites W2106584820 @default.
• W1958987550 cites W2107398329 @default.
• W1958987550 cites W2113271378 @default.
• W1958987550 cites W2114492363 @default.
• W1958987550 cites W2118120560 @default.
• W1958987550 cites W2118771330 @default.
• W1958987550 cites W2123355582 @default.
• W1958987550 cites W2129430680 @default.
• W1958987550 cites W2131095909 @default.
• W1958987550 cites W2131639268 @default.
• W1958987550 cites W2132191256 @default.
• W1958987550 cites W2132469484 @default.
• W1958987550 cites W2133682816 @default.
• W1958987550 cites W2140106230 @default.
• W1958987550 cites W2140419897 @default.
• W1958987550 cites W2144892629 @default.
• W1958987550 cites W2148428508 @default.
• W1958987550 cites W2149858388 @default.
• W1958987550 cites W2150754539 @default.
• W1958987550 cites W2158324181 @default.
• W1958987550 cites W2165036959 @default.
• W1958987550 cites W2165954541 @default.
• W1958987550 cites W2166041313 @default.
• W1958987550 cites W2169007954 @default.
• W1958987550 cites W2169476614 @default.
• W1958987550 cites W2169983938 @default.
• W1958987550 cites W2326726820 @default.
• W1958987550 cites W2522660978 @default.
• W1958987550 cites W2553652022 @default.
• W1958987550 cites W4232645703 @default.
• W1958987550 cites W4253412752 @default.
• W1958987550 doi "https://doi.org/10.1002/ajh.24102" @default.
• W1958987550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26294090" @default.

• next